Early initiation of diuretic therapy in patients with new onset cirrhotic ascites lowers 90-day mortality rate, according to a study in the American Journal of Gastroenterology. Researchers examined ...

J Gastroenterol Hepatol. 2009;24(9):1494-1503. Transjugular Intrahepatic Portosystemic Shunting. Transjugular intrahepatic portosystemic shunting (TIPS) creates an iatrogenic intrahepatic shunt a ...

Liver cirrhosis, a serious condition, can be managed with a holistic approach. Combining modern medicine with Ayurvedic ...

Use of rifaximin soluble solid dispersion tablets for up to 24 weeks did not increase infection-related adverse events among patients with cirrhosis, according to data presented at ACG Annual ...

Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of ...

CARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (BIVI), (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological ...

The patient underwent CT scan of the chest and abdomen. The chest CT showed only the lung lesions that are characteristic of PCP. Important cuts of the abdominal CT scan are shown in Figures 2 and 3.

FORT LAUDERDALE, Fla., Dec. 31, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF), a nonprofit dedicated to raising awareness, funding research, and supporting stomach cancer ...

Ghent, Belgium – 28 December 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...